Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$70.0 million","newsHeadline":"Merck Strengthens Oncology Portfolio Through Commercialization Agreement with Abbisko for Phase III Asset, Pimicotinib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Abbisko Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbisko Therapeutic Announces that EMA has Granted Orphan Drug Designation for its CSF-1R Inhibitor Pimicotinib (ABSK021)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Pimicotinib

    Menu

    Pimicotinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Abbisko Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Abbisko Therapeutic Announces that EMA has Granted Orphan Drug Designation for its CSF-1R Inhibitor Pimicotinib (ABSK021)

              Details:

              ABSK021 (pimicotinib) is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor. It is being evaluated in phase 3 studies for the treatment of inoperable tenosynovial giant cell tumor (TGCT).

              Lead Product(s): Pimicotinib

              Therapeutic Area: Oncology Product Name: ABSK021

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 08, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Abbisko Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021)

              Details:

              ABSK021 (pimicotinib) is a novel, orally available, highly selective, and potent small molecule CSF-1R inhibitor. It is being evaluated for for the treatment of tenosynovial giant cell tumor (TGCT).

              Lead Product(s): Pimicotinib

              Therapeutic Area: Oncology Product Name: ABSK021

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Abbisko Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Merck Strengthens Oncology Portfolio Through Commercialization Agreement with Abbisko for Phase III Asset, Pimicotinib

              Details:

              Under the agreement, Merck will receive an exclusive license to commercialize ABSK021 (pimicotinib), an oral, highly selective and potent small-molecule antagonist of colony stimulating factor-1 receptor, currently in Phase III for tenosynovial giant cell tumor.

              Lead Product(s): Pimicotinib

              Therapeutic Area: Oncology Product Name: ABSK021

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Merck Group

              Deal Size: Undisclosed Upfront Cash: $70.0 million

              Deal Type: Licensing Agreement December 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY